Comparison of the Primary Endpoint—Concentration of NT-proBNP at 12 Weeks.
Reproduced with permission from The Lancet; The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial. Solomon SD et al. 2012;doi:10.1016/S0140–6736(12)61227–6.